

Andreas Sellmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4670665/publications.pdf>

Version: 2024-02-01

18
papers

445
citations

840585

11
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

825
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. <i>Archives of Toxicology</i> , 2022, 96, 177-193.	1.9	10
2	A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. <i>Bioorganic Chemistry</i> , 2022, 119, 105505.	2.0	13
3	Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. <i>Cell Chemical Biology</i> , 2022, 29, 398-411.e4.	2.5	9
4	A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. <i>European Journal of Medicinal Chemistry</i> , 2020, 193, 112232.	2.6	8
5	HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β -catenin, MYC, and WT1. <i>Cancers</i> , 2019, 11, 1436.	1.7	27
6	Enantioselective synthesis and biological investigation of tetrahydro- β -carboline-based HDAC6 inhibitors with improved solubility. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900026.	2.1	4
7	Human platelet lysate as validated replacement for animal serum to assess chemosensitivity. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2019, 36, 277-288.	0.9	12
8	Design and biological evaluation of tetrahydro- β -carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 152, 329-357.	2.6	34
9	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3454-3477.	2.9	56
10	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. <i>Cellular Signalling</i> , 2017, 39, 9-17.	1.7	32
11	Class I histone deacetylases regulate p53/NF- κ B crosstalk in cancer cells. <i>Cellular Signalling</i> , 2017, 29, 218-225.	1.7	41
12	Generation and Assessment of Fusions Between HDACi and TKi. <i>Methods in Molecular Biology</i> , 2017, 1510, 405-412.	0.4	6
13	Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. <i>Archives of Toxicology</i> , 2017, 91, 2191-2208.	1.9	26
14	Drugging the HDAC6-HSP90 interplay in malignant cells. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 501-509.	4.0	110
15	Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. <i>MedChemComm</i> , 2012, 3, 829.	3.5	28
16	Synthesis of Naturally Occurring Pyrazine and Imidazole Alkaloids from <i>Botryllus</i> LeachiRID=?a?ID=?a?â€œDedicated to Prof. G . MÄrkl on the occasion of his 75 th birthday. <i>Monatshefte FÄ¼r Chemie</i> , 2004, 135, 333-342.	0.9	17
17	Electron Impact Induced Fragmentation of Aromatic Alkoxyimines II [5]. Formation and Transformation of Heterocyclic Radical Cations in the Gas Phase a. <i>Monatshefte FÄ¼r Chemie</i> , 2003, 134, 343-354.	0.9	9
18	On the Stereochemistry of Vincetene. <i>Monatshefte FÄ¼r Chemie</i> , 2001, 132, 765-768.	0.9	3